Skip to main content

Table 1 Demographic data and the small-bowel mucosal and serological findings of patients participating in the study

From: Small-intestinal TG2-specific plasma cells at different stages of coeliac disease

 

Prospectively studied coeliac patients

(n = 15)

Long-term treated coeliac patients

(n = 31)

Disease controls

(n = 25)

CD prior to atrophy

n = 14

Overt CD

n = 15

1 year GFD

n = 11

Patients in remission

n = 15

Non-responding CD

n = 11

Patients with dietary lapses

n = 5

Gluten sensitivity

n = 18

Dyspepsia

n = 7

Female; n (%)

10 (71)

10 (67)

7 (64)

10 (67)

7 (64)

5 (100)

16 (89)

1 (14)

Age; median (range), years

55 (16–70)

55 (17–71)

57 (28–72)

59 (24–66)

49 (40–76)

51 (31–77)

49 (24–65)

47 (24–76)

Duration of GFD; median (range), years

0

0

1 (1–1)

8 (3–34)

7 (3–24)

10 (9–17)

0

0

HLA-DQ2 or -DQ8-positive; n (%)

14 (100)

15 (100)

11 (100)

15 (100)

11 (100)

4a (100)

9 (50)

1 (14)

EmA; median (range), titer

1:100 (0–1:2000)

1:100 (0–1:4000)

0 (0–1:50)

0 (0)

0 (0–1:5)

1:200 (0–1:2000)

0 (0)

0 (0)

TG2 abs; median (range), U/ml

9.4 (3.3- > 100)

11.9 (4.2- > 100)

3.9 (0–8.6)

0.5 (0–2.8)

1.3 (0–9.9)

56.9 (12.9- > 100)

1.4 (0–4.1)

0.6 (0–2.8)

Mucosal TG2-IgA deposits present; n (%)

14 (100)

14a (100)

7b (88)

5 (33)

10a (100)

3c (100)

4 (22)

0 (100)

Vh/CrD; mean (95% CI), ratio

2.9 (2.6–3.1)

1.4 (1.1–1.7)

3.4 (2.4–4.5)

3.4 (3.2–3.6)

0.2 (0.0–0.4)

0.5 (−0.3–1.3)

3.5 (3.0–4.1)

3.5 (3.0–4.1)

CD3+ IELs; median

(range), cells/mm

54 (12–79)

67 (38–116)

39 (23–80)

42 (25–77)

60 (30–109)

50 (38–69)

21 (7–59)

26 (16–40)

αβ+ IELs; median

(range), cells/mm

30 (12–50)

43 (21–75)

22 (14–43)

31 (20–46)

44 (26–105)

38 (35–56)

16 (5–26)

22 (17–31)

γδ+ IELs; median

(range), cells/mm

18.8 (0–38.5)

23.7 (14–58.7)

v13.6 (1.4–56.3)

14.0 (7.3–27.8)

12.1 (0–37.8)

13.0 (4.4–20.5)

2.7 (0–10.2)

1.6 (0.7–16.1)

  1. abs antibodies, CD coeliac disease, CI confidence interval, EmA endomysial antibodies, GFD gluten-free diet, GS gluten sensitive; IgA immunoglobulin A; IELs intraepithelial lymphocytes; TG2-abs, transglutaminase 2 antibodies; Vh/CrD villous height crypt depth ratio
  2. Reference values set at 2.0 for Vh/CrD, 37 cells/mm for CD3+ IELs, 25 cells/mm for αβ+ IELs, and 4.3 cell/mm for γδ+ IELs (Järvinen et al., [15])
  3. Cut-off value for TG2 antibodies ≥ 5 AU/ml
  4. aData missing from one patient
  5. bData missing from three patients
  6. cData missing from two patients
Back to article page

BMC Immunology

ISSN: 1471-2172

Contact us